SCOPUS 정보 검색 플랫폼

British Journal of Cancer

Volumn 101, Issue 7, 2009, Pages 1222-1223

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

(1) Kalantari, H Rezaei a

a CH Peltzer La Tourelle ^* (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

SUNITINIB;

ADVANCED CANCER; AGED; ANEMIA; CANCER SURVIVAL; CASE REPORT; CLINICAL PRACTICE; CRACKED SKIN; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; EPISTAXIS; ERYTHRODERMA; FAINTNESS; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERTENSION; KIDNEY CANCER; LETTER; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; INDOLES; KIDNEY NEOPLASMS; MIDDLE AGED; PYRROLES;

EID: 70349653034 PISSN: 00070920 EISSN: 15321827 Source Type: Journal
DOI: 10.1038/sj.bjc.6605303 Document Type: Letter

Times cited : (7)

References (5)

1
- 35549008418
- Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/pharmacodynamic (PKPD) approach
- Houk BE, Bello CL, Michaelson MD, Bukowski RM, Redman BG, Hudes GR, Wilding G, Motzer RJ (2007) Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): a population pharmacokinetic/pharmacodynamic (PKPD) approach. J Clin Oncol 25: 5027
- (2007) J Clin Oncol , vol.25 , pp. 5027
- Houk, B.E.¹ Bello, C.L.² Michaelson, M.D.³ Bukowski, R.M.⁴ Redman, B.G.⁵ Hudes, G.R.⁶ Wilding, G.⁷ Motzer, R.J.⁸

2
- 52249112271
- Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma
- Kahl C, Hilgendorf I, Freund M, Casper J (2008) Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma. Onkologie 31: 485
- (2008) Onkologie , vol.31 , pp. 485
- Kahl, C.¹ Hilgendorf, I.² Freund, M.³ Casper, J.⁴

3
- 33846181370
- Sunitinib vs interferon alfa in metastatic renal-cell carcinoma
- Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib vs interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124
- (2007) N Engl J Med , vol.356 , pp. 115-124
- Motzer, R.J.¹ Hutson, T.E.² Tomczak, P.³ Michaelson, M.D.⁴ Bukowski, R.M.⁵ Rixe, O.⁶ Oudard, S.⁷ Negrier, S.⁸ Szczylik, C.⁹ Kim, S.T.¹⁰ Chen, I.¹¹ Bycott, P.W.¹² Baum, C.M.¹³ Figlin, R.A.¹⁴

4
- 66549086138
- Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: Case reports
- Schöffski P, Bukowski R, Flodgren P, Ravaud A (2009) Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours : case reports. Ann Oncol 20(Suppl 1): i25-i30
- (2009) Ann Oncol , vol.20 , Issue.SUPPL. 1
- Schöffski, P.¹ Bukowski, R.² Flodgren, P.³ Ravaud, A.⁴

5
- 48249107432
- Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
- van der Veldt AAM, Boven E, Helgason HH, van Wouwe M, Berkhof J, de Gast G, Mallo H, Tillier CN, van den Eertwegh AJM, Haanen JBAG (2008) Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 99: 259-265
- (2008) Br J Cancer , vol.99 , pp. 259-265
- Van Der Veldt, A.A.M.¹ Boven, E.² Helgason, H.H.³ Van Wouwe, M.⁴ Berkhof, J.⁵ De Gast, G.⁶ Mallo, H.⁷ Tillier, C.N.⁸ Van Den Eertwegh, A.J.M.⁹ Haanen, J.B.A.G.¹⁰

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.